Bernhard Maisch

List of Publications by Year
in descending order

255	16,921	30070 54	17105 122
papers	citations	h-index	g-index

294	294	294	14353
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	2.2	2,436
2	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	2.2	2,280
3	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	2.2	1,768
4	Guidelines on the Diagnosis and Management of Pericardial Diseases Executive SummaryThe Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. European Heart Journal, 2004, 25, 587-610.	2.2	1,127
5	Noninvasive Arrhythmia Risk Stratification in Idiopathic Dilated Cardiomyopathy. Circulation, 2003, 108, 2883-2891.	1.6	305
6	Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1024-1028.	3.6	299
7	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. European Heart Journal, 2011, 32, 1065-1076.	2.2	292
8	Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. American Journal of Cardiology, 1983, 52, 1072-1078.	1.6	212
9	The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). Herz, 2000, 25, 279-285.	1.1	185
10	Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-Î²B Ligand in Mol^nckebergâ€™s Sclerosis and Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4104-4112.	3.6	185
11	Definition of Inflammatory Cardiomyopathy (Myocarditis): On the Way to Consensus. Herz, 2000, 25, 200-209.	1.1	155
12	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	2.2	154
13	Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Human Pathology, 2003, 34, 497-503.	2.0	145
14	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. European Heart Journal, 2014, 35, 1069-1077.	2.2	137
15	Bacterial Pericarditis. American Journal of Cardiovascular Drugs, 2005, 5, 103-112.	2.2	131
16	Outcome of patients with sleep apneaâ€“associated severe bradyarrhythmias after continuous positive airway pressure therapy. American Journal of Cardiology, 2000, 86, 688-692.	1.6	128
17	Evaluation and Management of Pericardial Effusion in Patients with Neoplastic Disease. Progress in Cardiovascular Diseases, 2010, 53, 157-163.	3.1	125
18	Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. Journal of the American College of Cardiology, 1998, 32, 739-745.	2.8	122

#	Article	IF	Citations
19	Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. American Journal of Cardiology, 1996, 77, 1310-1314.	1.6	120
20	Inflammatory Dilated Cardiomyopathy (DCMI). Herz, 2005, 30, 535-544.	1.1	120
21	Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the â€˜Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)â€™ study. Europace, 2006, 8, 629-635.	1.7	110
22	Genetic Association Study Identifies HSPB7 as a Risk Gene for Idiopathic Dilated Cardiomyopathy. PLoS Genetics, 2010, 6, e1001167.	3.5	110
23	Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clinical Research in Cardiology, 2011, 100, 755-764.	3.3	101
24	Practical aspects of the management of pericardial disease. British Heart Journal, 2003, 89, 1096-1103.	2.1	96
25	Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. American Journal of Cardiology, 1995, 76, 8D-13D.	1.6	93
26	Osteoprotegerin Gene Polymorphisms in Men with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3764-3768.	3.6	88
27	Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. Journal of the American College of Cardiology, 2002, 39, 780-787.	2.8	86
28	Management Strategies in Pericardial Emergencies. Herz, 2006, 31, 891-900.	1.1	80
29	Pericardial syndromes: an update after the ESC guidelines 2004. Heart Failure Reviews, 2013, 18, 255-266.	3.9	77
30	Intrapericardial treatment of inflammatory and neoplastic pericarditis guided by pericardioscopy and epicardial biopsy-results from a pilot study. Clinical Cardiology, 1999, 22, 17-22.	1.8	76
31	Reversal of Tachycardia Induced Cardiomyopathy Following Ablation of Repetitive Monomorphic Right Ventricular Outflow Tract Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 166-171.	1.2	76
32	Heart rate variability in patients with cardiac hypertrophyâ€”Relation to left ventricular mass and etiology. American Heart Journal, 2006, 151, 829-836.	2.7	74
33	MR, CT, and PET imaging in pericardial disease. Heart Failure Reviews, 2013, 18, 289-306.	3.9	74
34	Complications of Third-Generation Implantable Cardioverter Defibrillator Therapy. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 206-211.	1.2	72
35	Antibodies Against Stress Proteins in Sera of Patients with Dilated Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 1997, 29, 2245-2251.	1.9	71
36	Detection ofPorphyromonas gingivalisDNA in Aortic Tissue by PCR. Journal of Periodontology, 2002, 73, 868-870.	3.4	70

#	Article	IF	Citations
37	Method for Aortic Wall Strain Measurement With Three-Dimensional Ultrasound Speckle Tracking and Fitted Finite Element Analysis. Annals of Thoracic Surgery, 2013, 96, 1664-1671.	1.3	70
38	Coxsackievirus B3 Infection Leads to Cell Death of Cardiac Myocytes. Journal of Molecular and Cellular Cardiology, 1994, 26, 907-913.	1.9	69
39	Autoantibodies in Sera of Patients with Myocarditis: Characterization of the Corresponding Proteins by Isoelectric Focusing and N-Terminal Sequence Analysis. Journal of Molecular and Cellular Cardiology, 1997, 29, 77-84.	1.9	69
40	Treatment of Inflammatory Dilated Cardiomyopathy and (Peri)Myocarditis with Immunosuppression and i.v. Immunoglobulins. Herz, 2004, 29, 624-636.	1.1	68
41	Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy. Basic Research in Cardiology, 2009, 104, 90-99.	5.9	68
42	QT Dispersion and Arrhythmic Events in Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 1996, 78, 458-461.	1.6	67
43	Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. European Journal of Heart Failure, 2011, 13, 1185-1192.	7.1	67
44	Prognostic Significance of Heart Rate Turbulence Following Ventricular Premature Beats in Patients with Idiopathic Dilated Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2003, 14, 819-824.	1.7	66
45	Immune reactions in tuberculous and chronic constrictive pericarditis. American Journal of Cardiology, 1982, 50, 1007-1013.	1.6	65
46	Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options. Frontiers in Cardiovascular Medicine, 2019, 6, 48.	2.4	65
47	Pathophysiology of viral myocarditis. Cardiovascular Pathology, 2002, 11, 112-122.	1.6	64
48	A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy. Molecular Genetics and Metabolism, 2008, 95, 74-80.	1.1	64
49	Pericardioscopy and epi- and pericardial biopsyâ€"a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Failure Reviews, 2013, 18, 317-328.	3.9	62
50	Clinical and immunologic characteristics in peripartum cardiomyopathy. International Journal of Cardiology, 2007, 118, 14-20.	1.7	61
51	Incidence rates and predictors of major and minor depression in patients with heart failure. International Journal of Cardiology, 2013, 167, 502-507.	1.7	60
52	Identification of mitochondrial antigens recognized by antibodies in sera of patients with idiopathic dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. American Journal of Cardiology, 1997, 80, 1040-1045.	1.6	59
53	Management of fulminant myocarditis: A diagnosis in search of its etiology but with therapeutic options. Current Heart Failure Reports, 2014, 11, 166-177.	3.3	59
54	Risk Stratification by the ?EPA+DHA Level? and the ?EPA/AA Ratio?. Herz, 2004, 29, 673-685.	1.1	58

#	Article	IF	Citations
55	The classification of pericardial disease in the age of modern medicine. Current Cardiology Reports, 2002, 4, 13-21.	2.9	57
56	Pericardial diseases, with a focus on etiology, pathogenesis, pathophysiology, new diagnostic imaging methods, and treatment. Current Opinion in Cardiology, 1994, 9, 379-388.	1.8	55
57	Increased enddiastolic wall stress precedes left ventricular hypertrophy in dilative heart failureâ€"Use of the volume-based wall stress index. International Journal of Cardiology, 2012, 157, 233-238.	1.7	54
58	Point Mutations in Mitochondrial DNA of Patients with Dilated Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 1997, 29, 2699-2709.	1.9	51
59	Cytokine Activation in Pericardial Fluids in Different Forms of Pericarditis. Herz, 2000, 25, 748-754.	1.1	51
60	Prevalence of Viral Genome in Endomyocardial Biopsies from Patients with Inflammatory Heart Muscle Disease. Herz, 2000, 25, 221-226.	1.1	49
61	Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Internal and Emergency Medicine, 2018, 13, 839-844.	2.0	48
62	Novel point mutations in the mitochondrial DNA detected in patients with dilated cardiomyopathy by screening the whole mitochondrial genome. Biochemical and Biophysical Research Communications, 2004, 318, 535-543.	2.1	46
63	Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2011, 13, 937-944.	7.1	46
64	Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Failure Reviews, 2013, 18, 761-795.	3.9	45
65	Pericardial Disease in Pregnancy. Herz, 2003, 28, 209-215.	1.1	44
66	Endomyocardial fibrosis in Churgâ€"Strauss syndrome assessed by cardiac magnetic resonance imaging. International Journal of Cardiology, 2006, 108, 112-113.	1.7	44
67	Assessment of antibody mediated cytolysis of adult cardiocytes isolated by centrifugation in a continuous gradient of percollTM in patients with acute myocarditis. Journal of Immunological Methods, 1981, 44, 159-169.	1.4	43
68	Effects of ACE Inhibition versus Non-ACE Inhibitor Antihypertensive Treatment on Myocardial Fibrosis in Patients with Arterial Hypertension. Herz, 2003, 28, 744-753.	1.1	43
69	Human viral cardiomyopathy. Frontiers in Bioscience - Landmark, 2003, 8, s39-67.	3.0	43
70	Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Failure Reviews, 2013, 18, 337-344.	3.9	43
71	Immune reactions in infective endocarditis. II. Relevance of circulating immune complexes, serum inhibition factors, lymphocytotoxic reactions, and antibody-dependent cellular cytotoxicity against cardiac target cells. American Heart Journal, 1983, 106, 338-344.	2.7	42
72	Invasive electrophysiological evaluation of patients with sleep apnoeaâ€associated ventricular asystoleâ€"methods and preliminary results. Journal of Sleep Research, 1995, 4, 160-165.	3.2	42

#	Article	IF	Citations
73	Pericardial access using the perDUCER and flexible percutaneous pericardioscopy. American Journal of Cardiology, 2001, 88, 1323-1326.	1.6	42
74	Cardiomyopathies: Classification, Diagnosis, and Treatment. Heart Failure Clinics, 2012, 8, 53-78.	2.1	42
75	Trypomastigotes and amastigotes of Trypanosoma cruzi induce apoptosis and STAT3 activation in cardiomyocytes in vitro. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 653-663.	4.9	42
76	Pericardial cytokines in neoplastic, autoreactive, and viral pericarditis. Heart Failure Reviews, 2013, 18, 345-353.	3.9	42
77	Activated nuclear transcription factor Î¤B in patients with myocarditis and dilated cardiomyopathyâ€"relation to inflammation and cardiac function. Biochemical and Biophysical Research Communications, 2006, 339, 180-187.	2.1	41
78	Periodontal Microbiota in Patients With Coronary Artery Disease Measured by Realâ€Time Polymerase Chain Reaction: A Caseâ€Control Study. Journal of Periodontology, 2007, 78, 1724-1730.	3.4	41
79	Immune reactions in infective endocarditis I. Clinical data and diagnostic relevance of antimyocardial antibodies. American Heart Journal, 1983, 106, 329-337.	2.7	40
80	Noninvasive Arrhythmia Risk Stratification in Idiopathic Dilated Cardiomyopathy: Design and First Results of the Marburg Cardiomyopathy Study. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2551-2556.	1.2	40
81	Heart Rate Variability and Major Arrhythmic Events in Patients with Idiopathic Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1841-1844.	1.2	39
82	Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour Holter electrocardiography. American Heart Journal, 2000, 140, 43-51.	2.7	39
83	Arrhythmia Risk Stratification with Regard to Prophylactic Implantable Defibrillator Therapy in Patients with Dilated Cardiomyopathy. Herz, 2004, 29, 348-352.	1.1	39
84	Recurrent pericarditis: mysterious or not so mysterious?. European Heart Journal, 2005, 26, 631-633.	2.2	39
85	A network against failing heartsâ€"Introducing the German â€œCompetence Network Heart Failureâ€. International Journal of Cardiology, 2010, 145, 135-138.	1.7	39
86	Antibodies to Human Sinus Node in Sick Sinus Syndrome.. PACE - Pacing and Clinical Electrophysiology, 1986, 9, 1101-1109.	1.2	38
87	Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Human Pathology, 2003, 34, 725-728.	2.0	38
88	Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. European Heart Journal, 2006, 27, 691-699.	2.2	38
89	Inflammation in Dilated Cardiomyopathy. Herz, 2004, 29, 788-793.	1.1	36
90	Viral genomes in the pericardial fluid and in peri- and epicardial biopsies from a German cohort of patients with large to moderate pericardial effusions. Heart Failure Reviews, 2013, 18, 329-336.	3.9	36

#	Article	IF	Citations
91	Antitachycardia Pacing for Spontaneous Rapid Ventricular Tachycardia in Patients with Prophylactic Cardioverter-Defibrillator Therapy. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 759-764.	1.2	34
92	Assessment of Cytomegalovirus DNA and Protein Expression in Patients with Myocarditis. Clinical Immunology and Immunopathology, 1993, 68, 229-233.	2.0	33
93	Drug withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovascular Drugs and Therapy, 1996, 10, 251-262.	2.6	33
94	Humoral Immune Reactions in Uremic Pericarditis. American Journal of Nephrology, 1983, 3, 264-271.	3.1	31
95	Influence of D-Net (European GSM-Standard) Cellular Phones on Pacemaker Function in 50 Patients with Permanent Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1456-1458.	1.2	31
96	Magnetic Resonance Imaging and Signal-Averaged Electrocardiography in Patients with Repetitive Monomorphic Ventricular Tachycardia and Otherwise Normal Electrocardiogram. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 1826-1833.	1.2	31
97	Novel mutations in the sarcomeric protein myopalladin in patients with dilated cardiomyopathy. European Journal of Human Genetics, 2013, 21, 294-300.	2.8	31
98	Immunosuppressive and immunomodulatory treatment for myocarditis. Current Opinion in Cardiology, 1996, 11, 310-324.	1.8	30
99	Molecular Mechanisms Involved in Atherosclerosis. Herz, 2002, 27, 637-648.	1.1	30
100	Heart Rate Turbulence following Ventricular Premature Beats in Healthy Controls. Annals of Noninvasive Electrocardiology, 2003, 8, 127-131.	1.1	30
101	Long Runs of Nonâ€Sustained Ventricular Tachycardia on 24â€Hour Ambulatory Electrocardiogram Predict Major Arrhythmic Events in Patients with Idiopathic Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S207-10.	1.2	30
102	Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs. International Journal of Cardiology, 2012, 156, 323-325.	1.7	30
103	Clinical Significance of Increased QT Dispersion in the 12-Lead Standard ECG for Arrhythmia Risk Prediction in Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1886-1889.	1.2	29
104	Sudden Cardiac Death in Dilated Cardiomyopathy - Therapeutic Options. Herz, 2002, 27, 750-759.	1.1	29
105	Effect of amiodarone on qt dispersion in the 12â€lead standard electrocardiogram and its significance for subsequent arrhythmic events. Clinical Cardiology, 1997, 20, 107-110.	1.8	28
106	Hyperlipidemia in Patients with Apolipoprotein E 2/2 Phenotype: Apolipoprotein A5 S19W Mutation as a Cofactor. Clinical Chemistry, 2004, 50, 2214-2214.	3.2	28
107	The 103I Variant of the Melanocortin 4 Receptor Is Associated with Low Serum Triglyceride Levels. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 535-538.	3.6	28
108	Dilated Cardiomyopathies as a Cause of Congestive Heart Failure. Herz, 2002, 27, 113-134.	1.1	27

#	Article	IF	Citations
109	How Many Patients with Dilated Cardiomyopathy May Potentially Benefit from Cardiac Resynchronization Therapy?. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 155-157.	1.2	27
110	Parvovirus B19 Genome in Endomyocardial Biopsy Specimen. Circulation, 2004, 109, e179.	1.6	27
111	Magnetic Resonance Imaging in Pericardial Diseases. Herz, 2006, 31, 708-714.	1.1	27
112	Management of Patients with Suspected (Peri-)Myocarditis and Inflammatory Dilated Cardiomyopathy. Herz, 2006, 31, 881-890.	1.1	27
113	Integrated Biomarkers in Cardiomyopathies. Herz, 2007, 32, 458-472.	1.1	27
114	Interventional Pericardiology. , 2011, , .		27
115	Dietary linolenic acid-mediated increase in vascular prostacyclin formation. Molecular and Cellular Biochemistry, 1996, 162, 59-64.	3.1	26
116	Epicardial halo phenomenon: a guide for pericardiocentesis?. Heart Failure Reviews, 2013, 18, 307-316.	3.9	26
117	Interactions between Pacemakers and Security Systems. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1784-1788.	1.2	25
118	Cytokines in Pericardial Effusion of Patients with Inflammatory Pericardial Disease. Mediators of Inflammation, 2012, 2012, 1-7.	3.0	25
119	Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. European Journal of Medical Research, 2007, 12, 243-8.	2.2	25
120	Usefulness of cytokines interleukin-6 and interleukin-2R concentrations in diagnosing active infective endocarditis involving native valves. American Journal of Cardiology, 2002, 89, 1400-1404.	1.6	24
121	Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis. International Journal of Cardiology, 2021, 324, 131-138.	1.7	24
122	Intrapericardial Treatment of Autoreactive Myocarditis with Triamcinolon Successful Administration in Patients with Minimal Pericardial Effusion. Herz, 2000, 25, 781-786.	1.1	23
123	Non-compaction cardiomyopathy in an adult with hereditary spherocytosis. European Journal of Heart Failure, 2007, 9, 98-99.	7.1	23
124	Glycosylphosphatidylinositol-induced cardiac myocyte death might contribute to the fatal outcome of PlasmodiumÂfalciparum malaria. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 857-866.	4.9	23
125	SARS-CoV-2 as potential cause of cardiac inflammation and heart failure. Is it the virus, hyperinflammation, or MODS?. Herz, 2020, 45, 321-322.	1.1	23
126	Value of Time- and Frequency-Domain Analysis of Signal-Averaged Electrocardiography for Arrhythmia Risk Prediction in Idiopathic Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1923-1927.	1.2	22

#	Article	IF	Citations
127	Pathophysiology of Cardiac Inflammation: Molecular Mechanisms. Herz, 2002, 27, 669-676.	1.1	22
128	Diagnosis and treatment of myocarditis: The role of endomyocardial biopsy. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 473-481.	0.9	22
129	Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy. European Journal of Human Genetics, 2010, 18, 694-699.	2.8	22
130	New Directions in Diagnosis and Treatment of Pericardial Disease A Project of the Taskforce on Pericardial Disease of the World Heart Federation. Herz, 2000, 25, 769-780.	1.1	21
131	Failure of Third-Generation Implantable Cardioverter Defibrillators to Abort Shock Therapy for onsustained Ventricular Tachycardia Due to Shortcomings of the VF Confirmation Algorithm. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 722-727.	1.2	20
132	Orcadian Variation and Onset Mechanisms of Ventricular Tachyarrhythmias in Patients with Coronary Disease Versus Idiopathic Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1939-1943.	1.2	20
133	Right Ventricular Cardiac Myxoma. Herz, 2005, 30, 663-667.	1.1	20
134	TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochemical and Biophysical Research Communications, 2005, 338, 1745-1750.	2.1	20
135	Association of hyperhomocysteinemia with left ventricular dilatation and mass in human heart. Clinical Chemistry and Laboratory Medicine, 2010, 48, 555-60.	2.3	20
136	Percutaneous Therapy in Pericardial Diseases. Cardiology Clinics, 2017, 35, 567-588.	2.2	20
137	Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury. Seminars in Immunopathology, 1989, 11, 369-95.	4.0	19
138	Significance of accelerated idioventricular rhythm in idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2000, 85, 899-904.	1.6	19
139	Prognostic Value of Heart Rate Variability Analysis in Patients with Carcinoid Syndrome. Digestion, 2001, 63, 35-42.	2.3	19
140	Gene expression profiling from endomyocardial biopsy tissue allows distinction between subentities of dilated cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 360-369.e1.	0.8	19
141	Activation of STAT1 transcription factor precedes up-regulation of coxsackievirusâ€“adenovirus receptor during viral myocarditis. Cardiovascular Pathology, 2008, 17, 81-92.	1.6	19
142	Vascular Endothelial Growth Factor in Malignant and Benign Pericardial Effusion. Clinical Cardiology, 2012, 35, 377-381.	1.8	19
143	Immunologic regulator and effector functions in perimyocarditis, postmyocarditic heart muscle disease and dilated cardiomyopathy. , 1986, 81 Suppl 1, 217-241.		19
144	Quantification of antimyosin antibodies in experimental myocarditis by a new solid phase fluorometric assay. Journal of Immunological Methods, 1983, 64, 239-247.	1.4	18

#	Article	IF	Citations
145	Four years of experience in endomyocardial biopsy â€"An immunohistologic approach. Heart and Vessels, 1985, 1, 59-67.	1.2	18
146	Heart Rate Variability During Head-up Tilt Testing in Patients with Suspected Neurally Mediated Syncope. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2411-2415.	1.2	18
147	Arrhythmias in Acute Pericarditis An Endomyocardial Biopsy Study. Herz, 2000, 25, 729-733.	1.1	18
148	Fatty acid oxidation inhibition with PPARÎ± activation (FOXIB/PPARÎ±) for normalizing gene expression in heart failure?. Cardiovascular Research, 2005, 66, 423-426.	3.8	18
149	Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in â€œHUFA deficiencyâ€• Canadian Journal of Physiology and Pharmacology, 2012, 90, 55-73.	1.4	18
150	HLA-DQB1* polymorphism and associations with dilated cardiomyopathy, inflammatory dilated cardiomyopathy and myocarditis^{â€}. Autoimmunity, 2009, 42, 33-40.	2.6	17
151	Cardiac Sarcoidosis: Cytokine Patterns in the Course of the Disease. Archives of Pathology and Laboratory Medicine, 2003, 127, 1207-1210.	2.5	17
152	Cardiac Rhythm and Conduction Disturbances: What is the Role of Autoimmune Mechanisms?. Herz, 2000, 25, 181-188.	1.1	16
153	Diagnosis of primary cardiac lymphoma by endomyocardial biopsy. American Journal of Medicine, 2001, 110, 593-594.	1.5	16
154	Plasmodium falciparum glycosylphosphatidylinositol induces limited apoptosis in liver and spleen mouse tissue. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1037-1041.	4.9	16
155	Isolated Cardiac Sarcoidosis Associated with the Expression of a Splice Variant Coding for a Truncated BTNL2 Protein. Cardiology, 2008, 109, 117-121.	1.4	16
156	Inflammatory dilated cardiomyopathy. Herz, 2020, 45, 221-229.	1.1	16
157	Association of right ventricular dysfunction and Cheyne-Stokes respiration in patients with chronic heart failure. Journal of Sleep Research, 2003, 12, 161-167.	3.2	15
158	Familial inflammatory dilated cardiomyopathy. European Journal of Heart Failure, 2006, 8, 816-825.	7.1	15
159	N-3 polyunsaturated fatty acids and statins in heart failure. Lancet, The, 2009, 373, 378-379.	13.7	15
160	Immunologic regulator and effector mechanisms in myocarditis and perimyocarditis. Heart and Vessels, 1985, 1, 209-217.	1.2	14
161	Rickettsial perimyocarditisâ€"A follow-up study. Heart and Vessels, 1986, 2, 55-59.	1.2	14
162	Flexible Percutaneous Pericardioscopy: Inherent Drawbacks and Recent Advances. Herz, 2000, 25, 741-747.	1.1	14

#	Article	IF	Citations
163	Prediction of Major Arrhythmic Events and Sudden Cardiac Death in Dilated Cardiomyopathy. Herz, 2000, 25, 189-199.	1.1	14
164	Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy. American Heart Journal, 2003, 146, 372-376.	2.7	14
165	Outcomes of Elderly Recipients of Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S134-8.	1.2	14
166	Evaluation of the presence of selected viral and bacterial nucleic acids in pericardial samples from dogs with or without idiopathic pericardial effusion. Veterinary Journal, 2009, 179, 225-229.	1.7	14
167	Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the German Competence Network Heart Failure. Zeitschrift Fur Gesundheitswissenschaften, 2012, 20, 23-30.	1.6	14
168	Arrhythmia Risk Prediction in Idiopathic Dilated Cardiomyopathy Based on Heart Rate Variability and Baroreflex Sensitivity. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S202-S206.	1.2	13
169	Molecular Basis of Obesity and the Risk for Cardiovascular Disease. Herz, 2006, 31, 200-206.	1.1	13
170	Acute Heart Failureâ€"Basic Pathomechanism and New Drug Targets. Herz, 2006, 31, 727-735.	1.1	13
171	Genotypeâ€specific effects on left ventricular function in parvovirus B19â€positive patients with dilated cardiomyopathy. Journal of Medical Virology, 2011, 83, 1818-1825.	5.0	13
172	Detection of anti-hsp70 immunoglobulin G antibodies indicates better outcome in coronary artery bypass grafting patients suffering from severe preoperative angina. Annals of Thoracic Surgery, 2004, 78, 883-889.	1.3	12
173	Management of Pericardial Effusion. Herz, 2005, 30, 144-150.	1.1	12
174	Assessment and relevance of ventricular wall stress in heart failure. European Heart Journal, 2008, 29, 2316-2316.	2.2	12
175	Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clinical Biochemistry, 2012, 45, 237-242.	1.9	12
176	Radiotelemetric characterization of overweight-associated rises in blood pressure and heart rate. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1540-H1545.	3.2	11
177	Transient QT Prolongation with Torsades de Pointes Tachycardia after Ablation of Permanent Junctional Reciprocating Tachycardia. Journal of Cardiovascular Electrophysiology, 1999, 10, 1631-1635.	1.7	11
178	Mitochondrial DNA Deletions in Cardiomyopathies. Herz, 2000, 25, 161-167.	1.1	11
179	Depression of Heart Rate Variability in Patients with Increased Ventricular Wall Stress. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S26-31.	1.2	11
180	Different Profile of Antioxidative Capacity Results in Pulmonary Dysfunction and Amplified Inflammatory Response After CABG Surgery. Journal of Surgical Research, 2007, 139, 136-142.	1.6	10

#	Article	IF	Citations
181	Sleepâ€Disordered Breathing in Recipients of Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S8-11.	1.2	10
182	The Biomaterialbank of the German Competence Network of Heart Failure (CNHF) is a valuable resource for biomedical and genetic research. International Journal of Cardiology, 2009, 136, 108-111.	1.7	10
183	Alcohol ablation of pericardial cysts under pericardioscopical control. Heart Failure Reviews, 2013, 18, 361-365.	3.9	10
184	Humoral immune response to cardiac conducting tissue. Seminars in Immunopathology, 1989, 11, 409-22.	4.0	9
185	Atrial Natriuretic Peptide Levels Reflect Hemodynamic Changes Under Pacemaker Stimulation. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 970-975.	1.2	9
186	Control of apoptosis of cardiovascular fibroblasts: A novel drug target. Herz, 1999, 24, 225-231.	1.1	9
187	Lipids and Lipoproteins in Women. Herz, 2005, 30, 368-374.	1.1	9
188	Failure of omega-3 fatty acids in atrial fibrillation? No deficiency of highly unsaturated fatty acids in the absence of heart failure. Europace, 2011, 13, 1357-1357.	1.7	9
189	Acute and RecurrentÂPericarditis. Journal of the American College of Cardiology, 2017, 69, 2775.	2.8	9
190	Humoral and Cellular Immune Response in Human Myocarditis and Dilated Cardiomyopathy. Pathology and Immunopathology Research, 1988, 7, 240-250.	0.8	8
191	How cardiac cells die â€" Necrosis, oncosis and apoptosis. Herz, 1999, 24, 181-188.	1.1	8
192	Semi-Automated Rapid Isoelectric Focusing of Apolipoproteins C from Human Plasma Using PhastSystemâ„¢ and Immunofixation. Clinical Chemistry and Laboratory Medicine, 1999, 37, 643-8.	2.3	8
193	Relation Between Microvolt Level T Wave Alternans and Other Potential Noninvasive Predictors of Arrhythmic Risk in the Marburg Cardiomyopathy Study. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1960-1964.	1.2	8
194	Control of cardiomyocyte gene expression as drug target. Molecular and Cellular Biochemistry, 2000, 212, 135-142.	3.1	8
195	Biomarkers in Inflammatory and Noninflammatory Cardiomyopathy. Herz, 2009, 34, 614-623.	1.1	8
196	Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clinical Research in Cardiology, 2012, 101, 829-836.	3.3	8
197	Effusive-constrictive pericarditis: current perspectives. Journal of Vascular Diagnostics and Interventions, 0, Volume 6, 7-14.	0.0	8
198	Percutaneous Balloon Pericardiotomy. , 2011, , 155-161.		8

#	Article	IF	Citations
199	Surface antigens of adult heart cells and their use in diagnosis. , 1984, 80 Suppl 1, 47-51.		8
200	Heart rate variability in carcinoid heart disease. American Journal of Cardiology, 1999, 83, 128-131.	1.6	7
201	Mutations in MYOZ1 as well as MYOZ2 encoding the calsarcins are not associated with idiopathic and familial dilated cardiomyopathy. Molecular Genetics and Metabolism, 2007, 91, 207-208.	1.1	7
202	COVID-19â€"What we know and what we need to know: There are more questions than answers. Herz, 2020, 45, 311-312.	1.1	7
203	Are antisarcolemmal (ASAs) and antimyolemmal antibodies (AMLAs) â€œnaturalâ€•antibodies?. , 1991, 86 Suppl 3, 101-114.		7
204	Simplified Implantation of Single-Lead Pectoral Cardioverter Defibrillators Using Device-Based Testing. American Journal of Cardiology, 1998, 81, 503-506.	1.6	6
205	Detection of Viral and Bacterial Protein in Endomyocardial Biopsies of Patients with Inflammatory Heart Muscle Disease?. Herz, 2000, 25, 233-239.	1.1	6
206	Phenotype of Infiltrating T Lymphocytes in Cardiac Sarcoidosis. Circulation, 2002, 105, e67-8.	1.6	6
207	Influence of different aetiologies on clinical course and outcome in patients with dilated cardiomyopathy. European Journal of Clinical Investigation, 2015, 45, 906-917.	3.4	6
208	Anti-viral and anti-myocyte antibodies in experimental myocarditis. Seminars in Immunopathology, 1989, 11, 69-76.	4.0	5
209	Autoreactive mechanisms in infective endocarditis. Seminars in Immunopathology, 1989, 11, 439-56.	4.0	5
210	Autoimmunity in dilated cardiomyopathy. Heart Failure Reviews, 1996, 1, 173-182.	3.9	5
211	Cardiac autonomic tone and its relation to nonsustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Clinical Cardiology, 2000, 23, 103-108.	1.8	5
212	Early occurrence of septic pericarditis after nissen fundoplication. American Journal of Medicine, 2003, 115, 507-508.	1.5	5
213	Separation of large mammalian ventricular myosin differing in ATPase activityThis paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 326-331.	1.4	5
214	Anticardiac Antibodies in Patients with Chronic Pericardial Effusion. Disease Markers, 2016, 2016, 1-4.	1.3	5
215	Cardiocytolytic antimyolemmal antibodies in dilated cardiomyopathy following presentation: observations in 7 patients. International Journal of Cardiology, 1993, 38, 133-140.	1.7	4
216	Baroreflex Sensitivity and Heart Rate Variability in Coronary Disease Compared to Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2416-2419.	1.2	4

#	Article	IF	Citations
217	Matrix Metalloproteinases and Their Inhibitors in Malignant and Autoreactive Pericardial Effusion. American Journal of Cardiology, 2005, 95, 1065-1069.	1.6	4
218	HSPA1B polymorphism in familial forms of inflammatory dilated cardiomyopathy. International Journal of Cardiology, 2009, 133, 126-128.	1.7	4
219	Pericardial diseases in the era of imaging, biomarkers and molecular diagnosis. Heart Failure Reviews, 2013, 18, 251-254.	3.9	4
220	Cardiomyopathy and myocarditis â€" A review of new aspects in research in West Germany. Heart and Vessels, 1985, 1, 8-13.	1.2	3
221	Strategies to Optimize CAD Prevention in Modern Cardiology The â€œMarburg CAD Prevention Projectâ€: Herz, 2000, 25, 113-116.	1.1	3
222	Restenosis after Percutaneous Coronary Interventions and Infection. Herz, 2000, 25, 91-94.	1.1	3
223	Pathophysiological Mechanisms of Parvovirus B19 Infection. Journal of Clinical Microbiology, 2009, 47, 2358-2359.	3.9	3
224	Behind the Curtain of Pericardial Tamponade: Cardiac Hemangioendotheliosarcoma. Herz, 2009, 34, 161-162.	1.1	3
225	Immunological features in a case of hypereosinophilic syndrome and myocarditis. Heart and Vessels, 1990, 5, 237-242.	1.2	2
226	Characterization of sucrose-induced changes in cardiac phenotype. Pflugers Archiv European Journal of Physiology, 2002, 445, 32-39.	2.8	2
227	Biomarker and no end to it?. Herz, 2009, 34, 579-580.	1.1	2
228	Akute und chronische Perikarditis. , 2014, , 1-19.		2
229	Predictive Value of QT Dispersion for Ventricular Tachyarrhythmias in Patients with Implantable Cardioverter Defibrillator. Annals of Noninvasive Electrocardiology, 1996, 1, 419-422.	1.1	1
230	Incidence and Clinical Significance of Ventricular Late Potentials in Idiopathic Dilated Cardiomyopathy Compared to Coronary Artery Disease. Annals of Noninvasive Electrocardiology, 1997, 2, 20-26.	1.1	1
231	Pericardial effusion and non-constrictive diastolic dysfunction in acromegaly. European Journal of Radiology Extra, 2006, 58, 81-84.	0.1	1
232	Pericardial Access and Drainage: Standard Techniques. , 2011, , 33-53.		1
233	Alternative Techniques for Pericardiocentesis. , 2011, , 55-75.		1
234	Pericardiocentesis in the Absence of Effusion. , 2011, , 77-86.		1

#	Article	IF	Citations
235	Comparison of Baroreflex Sensitivity with Age and Indices of Left Ventricular Function in Patients with Dilated Cardiomyopathy. Annals of Noninvasive Electrocardiology, 1999, 4, 67-71.	1.1	0
236	Linear Lesion Formation by ND:YAG Laser Versus Radiofrequency Energy in Porcine Atria. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1848-1851.	1.2	0
237	Schlagen Frauenherzen wirklichanders?. Herz, 2005, 30, 353-355.	1.1	0
238	Adding colchicine to aspirin may prevent recurrence of acute pericarditis. Evidence-based Cardiovascular Medicine, 2006, 10, 64-66.	0.0	0
239	Akute Herzinsuffizienz. Herz, 2006, 31, 725-726.	1.1	0
240	Reply to letter from Josef Finsterer and Claudia Stollberger. European Journal of Heart Failure, 2007, 9, 101-101.	7.1	0
241	Dilated Cardiomyopathy â€“ a Syndrome, not a Homogeneous Disease. Herz, 2007, 32, 444-445.	1.1	0
242	Demonstration of TGF-? and XIII? in Endocardial Biopsies of Carcinoid Heart Disease Patients: an Immunofluorescence Study. Cardiology Research, 2011, 2, 119-122.	1.1	0
243	Diagnostic Value of Pericardial Fluid Analyses. , 2011, , 87-109.		0
244	Cardiomyopathiesâ€”past, present, future. Herz, 2020, 45, 209-211.	1.1	0
245	Humorale Immunreaktionen bei viraler und autoimmuner inflammatorischer Kardiomyopathie â€” Retrospektive und Perspektive. , 2001, , 24-48.		0
246	Dilated Cardiomyopathies and Congestive Heart Failure. Progress in Experimental Cardiology, 2003, , 35-65.	0.0	0
247	Pathogenesis, diagnosis and treatment of pericarditis. , 2010, , 3-24.		0
248	Intrapericardial Treatment in Pericardial Disease. , 2011, , 135-153.		0
249	Pericardial Effusion and Cardiac Tamponade. , 2011, , 21-32.		0
250	Epicardial and Pericardial Biopsy. , 2011, , 123-134.		0
251	Anatomy of the Pericardium Relevant for Pericardial Access, Pericardioscopy, and Intrapericardial Interventions. , 2011, , 15-20.		0
252	A Historical Perspective. , 2011, , 1-13.		0

#	Article	IF	Citations
253	Pericardiosopy: Endoscopic Insight in Pericardial and Epicardial Pathology. , 2011, , 111-121.		0
254	Posttranscriptional Gene Silencing. , 2009, , 109-120.		0
255	Toll-Like Receptors: Potential Targets for Therapeutic Interventions. , 2009, , 749-755.		0